larg
quantiti
sarscov
viru
prolifer
vero
cell
inactiv
propiolacton
purifi
sepharos
column
chromatographi
prepar
inactiv
vaccin
vaccin
identifi
western
blot
mass
spectrograph
analysi
elisa
electron
microscopi
vaccin
without
aluminum
hydroxid
adjuv
inocul
femal
balbc
mice
differ
dosag
result
show
antibodi
sarscov
induc
mice
antibodi
level
induc
vaccin
aluminum
hydroxid
higher
without
aluminum
hydroxid
sever
acut
respiratori
syndrom
sar
one
seriou
emerg
diseas
china
past
sever
decad
caus
novel
coronaviru
wide
spread
common
popul
symptom
diseas
sever
mortal
patient
high
present
research
show
diseas
mainli
transmit
droplet
respiratori
tract
mucosa
accord
experi
control
infecti
diseas
vaccin
would
effect
measur
prevent
epidem
sar
studi
began
develop
inactiv
sar
vaccin
report
describ
procedur
prepar
inactiv
vaccin
cultiv
sar
viru
vero
cell
besid
immun
vaccin
mice
report
viru
cell
sarscov
strain
isol
patient
beij
institut
microbiolog
epidemiolog
academi
militari
medicin
whole
genom
strain
sequenc
sequenc
submit
genbank
access
ncbiay
vero
cell
provid
nation
vaccin
serum
institut
special
use
vaccin
product
cell
meet
relev
requir
requir
biolog
peopl
republ
china
prepar
vaccin
vero
cell
infect
sarscov
strain
incub
serumfre
medium
ml
per
bottl
h
infect
titer
reach
tcid
cell
lyse
freez
thaw
centrifug
rmin
beckman
min
supernat
harvest
ad
dilutedpropiolacton
sigma
shaken
incub
h
inactiv
sampl
stood
h
hydrolyz
propiolacton
inactiv
viru
suspens
centrifug
rmin
beckman
min
supernat
harvest
concentr
sigma
origin
volum
concentr
centrifug
g
min
use
cetriplu
millipor
purifi
sepharos
column
chromatographi
cm
diamet
cm
length
flow
rate
mlmin
fraction
analyz
sdspage
data
shown
harvest
virus
pool
concentr
centrifug
use
total
protein
content
sampl
chromatographi
measur
lowri
method
human
albumin
stabil
thimeros
antisept
ad
purifi
viru
sampl
taken
purifi
viru
examin
electron
microscopi
western
blot
elisa
mass
spectrograph
analysi
dosag
antigen
final
adjust
pb
prepar
pure
antigen
contain
aluminum
hydroxid
adjuv
follow
procedur
adopt
aluminum
hydroxid
nation
vaccin
serum
institut
ad
antigen
solut
final
concentr
mgml
shaken
h
make
antigen
adsorb
onto
adjuv
complet
immun
test
anim
sixweekold
femal
balbc
mice
purchas
beij
weitonglihua
ltd
co
laboratori
anim
techniqu
mice
divid
sever
group
inocul
differ
dosag
inactiv
vaccin
vaccin
plu
aluminum
hydroxid
adjuv
respect
mous
inject
ip
twice
interv
three
week
sera
detect
igg
elisa
collect
orbit
mice
three
week
first
inject
heart
one
week
second
inject
elisa
perform
sequenti
solid
phase
polystyren
plate
ladder
reagent
consist
first
purifi
sarscov
viru
second
twofold
dilut
serum
third
biotinlabel
goat
antimous
igg
chain
specif
southern
biotechnolog
associ
inc
usa
fourth
streptavidinconjug
alkalin
phosphatas
southern
biotechnolog
associ
inc
usa
final
pnitrophenylphosph
chromogen
product
measur
absorb
nm
aid
autoread
labsystem
muliskan
ascent
thermo
bioanalysi
compani
finland
amplifi
vero
cell
sarscov
harvest
inactiv
dilut
propiolacton
sampl
concentr
centriplu
ym
centrifug
purifi
sepharos
column
chromatographi
shown
fig
two
peak
appear
sepharos
chromatogram
electronmicroscop
inspect
viral
particl
nm
typic
corona
spike
could
observ
elut
first
peak
fig
similar
particl
elut
second
therefor
sarscov
appear
first
peak
macroprotein
second
peak
fraction
contain
sar
viru
pool
condens
prepar
inactiv
vaccin
sarscov
propiolacton
employ
inactiv
viru
ratio
sampl
taken
h
inactiv
respect
put
h
hydrolyz
propiolacton
infect
residu
viru
examin
inocul
sampl
vero
cell
three
blind
passag
result
show
viru
could
complet
inactiv
propiolacton
dilut
h
h
purifi
sar
viru
subject
sdspage
see
fig
reduc
condit
transfer
onto
millipor
immobilonp
pvdf
membran
membran
block
ttb
contain
nonfat
milk
powder
min
incub
dilut
serum
antisar
posit
patient
beij
region
ttb
overnight
bound
antibodi
detect
use
appropri
alkalin
phosphataseconjug
goat
antihuman
igg
ttb
follow
nitroblu
tetrazolium
chlorid
nbt
indolyphosph
ptoluidin
salt
bcip
develop
antisar
posit
sera
react
mainli
kd
band
repres
n
protein
respect
mass
spectrograph
analysi
band
n
protein
cut
sdspage
gel
fig
use
malditof
analysi
shown
fig
two
band
identifi
n
protein
sarscov
accord
ms
data
sarscov
provid
ncbi
elisa
inactiv
vaccin
confirm
elisa
method
use
kit
sar
detect
beij
huadajibiai
ltd
co
biotech
prepar
vaccin
subject
ultrason
dissolut
use
moll
urea
use
coat
elisa
plate
suggest
manufactur
use
sera
sar
patient
normal
human
first
antibodi
strong
posit
result
observ
use
sar
sera
compar
control
sera
normal
human
immun
protocol
mice
divid
group
mice
per
group
group
inocul
vaccin
without
adjuv
anoth
group
vaccin
contain
aluminum
hydroxid
adjuv
dosag
g
respect
rest
group
set
blank
control
tabl
mous
inocul
two
dose
interv
three
week
mice
sera
collect
three
week
first
dose
one
week
second
dose
detect
serum
antibodi
immun
respons
immun
respons
mice
inocul
inactiv
vaccin
without
aluminum
hydroxid
adjuv
variou
dosag
shown
tabl
result
summar
follow
antibodi
level
induc
two
dose
vaccin
significantli
higher
one
dose
larger
dosag
vaccin
higher
antibodi
titer
induc
antibodi
level
induc
vaccin
aluminum
hydroxid
adjuv
slightli
hig
er
without
adjuv
h
method
inactiv
purif
sarscov
viru
report
paper
studi
prove
inactiv
vaccin
prepar
prolifer
sarscov
viru
vero
cell
inactiv
propiolacton
purif
sepharos
column
chromatographi
induc
antibodi
mice
provid
practic
basi
develop
effect
vaccin
immun
protocol
product
procedur
adjuv
vaccin
discuss
follow
immun
protocol
sinc
first
paper
report
research
inactiv
sarscov
vaccin
sar
new
viral
diseas
immun
schedul
refer
accord
experi
develop
influenza
vaccin
set
schedul
inocul
two
dose
interv
three
week
mice
bled
three
week
first
dose
one
week
second
dose
detect
serum
antibodi
result
show
either
one
dose
two
dose
vaccin
induc
good
immun
respons
present
twodos
schedul
adopt
immun
inactiv
influenza
vaccin
show
good
effect
howev
protect
effect
least
partial
protect
effect
one
dose
influenza
vaccin
report
recent
basi
experi
develop
vaccin
respiratori
diseas
consid
immun
effect
two
dose
vaccin
satisfactori
epidem
period
emerg
condit
whether
singl
dose
inactiv
sarscov
vaccin
provid
protect
partial
protect
effect
studi
clinic
trial
howev
result
clinic
trial
shall
determin
two
epidem
period
product
procedur
inactiv
vaccin
procedur
product
inactiv
sar
vaccin
primarili
establish
paper
select
propiolacton
inactiv
viru
kind
alkyl
agent
could
react
nucleic
acid
propiolacton
could
break
structur
nucleic
acid
reaction
purin
base
mainli
guanin
alkyl
agent
could
either
form
gap
insid
dna
caus
cross
link
doubl
strand
dna
wide
use
inactiv
dna
rna
virus
could
detect
residu
live
viru
vaccin
inactiv
prove
propiolacton
suitabl
prepar
inactiv
sarscov
vaccin
inactiv
select
sepharos
column
chromatographi
purifi
viru
particl
antibodi
detect
level
mice
immun
crude
antigen
data
shown
consid
might
due
influenc
interfer
heteroprotein
normal
immun
respons
anim
result
studi
show
product
purif
procedur
establish
met
requir
anim
test
procedur
suitabl
largescal
product
studi
adjuv
aluminum
hydroxid
select
studi
safe
adjuv
recommend
wide
use
variou
viral
bacteri
vaccin
includ
dtp
aluminum
hydroxid
insolubl
colloid
precipit
particl
size
antigen
bound
colloid
static
electr
adsorb
onto
aluminum
hydroxid
antigen
form
storag
pool
inocul
site
releas
slowli
may
caus
local
inflammatori
reaction
attract
activ
lymphocyt
enhanc
immun
respons
also
activ
complement
system
studi
show
antibodi
level
induc
vaccin
aluminum
hydroxid
adjuv
higher
without
adjuv
howev
whether
sarscov
vaccin
futur
contain
aluminum
hydroxid
adjuv
need
studi
prospect
studi
show
might
success
develop
effect
vaccin
prevent
sarscov
still
lot
work
field
perhap
scientist
object
purif
method
even
inactiv
vaccin
may
anxiou
safeti
inactiv
vaccin
wonder
rna
strand
complet
broken
propiolacton
case
individu
viru
particl
contain
incomplet
broken
rna
strand
problem
safeti
may
occur
scientist
may
suggest
develop
subunit
vaccin
subunit
vaccin
shall
technic
feasibl
product
cost
expens
howev
unlik
antigen
determin
inactiv
vaccin
natur
state
develop
recombin
immunogen
mimic
oligomer
present
protein
found
viru
particl
may
difficult
meanwhil
whether
singl
gene
multipl
gene
shall
select
prepar
subunit
vaccin
verifi
studi
anoth
problem
face
us
whether
current
strain
individu
repres
sarscov
preval
winter
whether
wide
vari
still
unclear
field
product
also
problem
largescal
manufactur
inactiv
sarscov
vaccin
sinc
prolifer
larg
quantiti
viru
perform
laboratori
attenu
strain
select
use
product
vaccin
instead
current
sarscov
strain
abovement
problem
hope
solv
fact
work
solv
problem
alreadi
progress
paper
describ
inactiv
purif
sar
viru
prepar
inactiv
vaccin
immunogen
vaccin
benefici
scientist
engag
research
sar
vaccin
